Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

HIV genotype resistance testing in antiretroviral (ART) exposed Indian children--a need of the hour.

Shah I, Parikh S.

Indian J Pediatr. 2013 Apr;80(4):340-2. doi: 10.1007/s12098-012-0752-6. Epub 2012 Apr 29.

PMID:
22544694
2.

HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S.

Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):83-8.

PMID:
19323038
3.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
4.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
5.

Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.

Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE.

AIDS Patient Care STDS. 2007 Aug;21(8):544-50.

PMID:
17711379
6.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

7.

[Clinical use of HIV-1 resistance genotyping. Predictive factors of poor virological evolution in salvage treatments].

Riera-Jaume M, Peñaranda-Vera M, Ribas-Blanco MA, Murillas-Angoiti J, Campins A, Salas-Aparicio A, Leyes-García M, Pareja-Bezares A, Pérez JL, Villalonga-Pieras C.

Enferm Infecc Microbiol Clin. 2006 Apr;24(4):225-31. Spanish.

PMID:
16725081
9.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
10.

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Niubó J, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR Study Team.

Antivir Ther. 2012;17(3):577-83. doi: 10.3851/IMP2025. Epub 2011 Dec 19. Erratum in: Antivir Ther. 2012;17(3):597.

PMID:
22301439
11.

Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.

Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1179-85. doi: 10.1089/aid.2009.0110.

PMID:
19895208
12.

Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.

Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.

Pediatr Infect Dis J. 2006 Nov;25(11):1049-56.

PMID:
17072129
13.

Antiretroviral drug resistance among HIV-1 infected children failing treatment.

Mullen J, Leech S, O'Shea S, Chrystie IL, Du Mont G, Ball C, Sharland M, Cottam F, Zuckerman M, Rice P, Easterbrook P.

J Med Virol. 2002 Nov;68(3):299-304.

PMID:
12226814
14.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
15.

Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34.

PMID:
21694603
16.

Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.

Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, Antinori A.

Antivir Ther. 2003 Feb;8(1):51-6.

PMID:
12713064
17.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

PMID:
17205457
18.

Genotype testing and antiretroviral resistance profiles from HIV-1 patients experiencing therapeutic failure in northeast Brazil.

Medeiros MS, Arruda EA, Guerrant RL, Brown C, Hammarskjold ML, Rekosh D, Lima AA.

Braz J Infect Dis. 2007 Aug;11(4):390-4. Erratum in: Braz J Infect Dis. 2007 Oct;11(5):528-9.

19.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
20.

Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.

Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Kaudha E, Mukuye A, Matama C, Nankya I, Nakatudde L, Dekker JT, Hamers RL, Mugyenyi P, Rinke De Wit TF, Kityo C.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):925-30. doi: 10.1089/AID.2012.0218. Epub 2013 Apr 17.

PMID:
23517497

Supplemental Content

Support Center